Review
doi: 10.1038/nrn1495.
Strategies for disease modification in Alzheimer's disease
Affiliations
- PMID: 15322526
- DOI: 10.1038/nrn1495
Item in Clipboard
Review
Strategies for disease modification in Alzheimer's disease
Nat Rev Neurosci.
2004 Sep.
Abstract
Treating Alzheimer's disease (AD) is the biggest unmet medical need in neurology. Current drugs improve symptoms, but do not have profound disease-modifying effects. Three main classes of disease-modification approaches can be defined: one that is broadly neurotrophic or neuroprotective, one that targets specific aspects of AD pathology, and one that is based on epidemiological observation. This review discusses all three approaches, with particular emphasis on anti-amyloid strategies - currently the most active area of investigation. The approaches that are reviewed include secretase inhibition, amyloid-beta aggregation inhibition, immunotherapy and strategies that might indirectly affect the amyloid pathway.
Similar articles
-
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.Prog Neurobiol. 2007 Aug;82(6):348-60. doi: 10.1016/j.pneurobio.2007.06.001. Epub 2007 Jun 19. Prog Neurobiol. 2007. PMID: 17659826 Review.
-
Alzheimer's disease: treatments in discovery and development.Nat Neurosci. 2002 Nov;5 Suppl:1055-7. doi: 10.1038/nn940. Nat Neurosci. 2002. PMID: 12403985 Review.
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
-
Alzheimer's disease: from pathology to therapeutic approaches.Angew Chem Int Ed Engl. 2009;48(17):3030-59. doi: 10.1002/anie.200802808. Angew Chem Int Ed Engl. 2009. PMID: 19330877 Review.
-
[Alzheimer's disease: from brain lesions to new drugs].Bull Acad Natl Med. 2008 Feb;192(2):363-78; discussion 378-80. Bull Acad Natl Med. 2008. PMID: 18819689 Review. French.
Cited by
-
Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Int J Mol Sci. 2015 May 8;16(5):10578-600. doi: 10.3390/ijms160510578. Int J Mol Sci. 2015. PMID: 26006227 Free PMC article. Review.
-
Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).Arch Med Sci. 2011 Feb;7(1):102-11. doi: 10.5114/aoms.2011.20612. Epub 2011 Mar 8. Arch Med Sci. 2011. PMID: 22291741 Free PMC article.
-
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.Neurobiol Dis. 2020 Oct;144:105010. doi: 10.1016/j.nbd.2020.105010. Epub 2020 Jul 16. Neurobiol Dis. 2020. PMID: 32682954 Free PMC article. Review.
-
An individualized approach to treatment for alzheimer's disease, pick's disease, and other dementias.Am J Alzheimers Dis Other Demen. 2006 Oct-Nov;21(5):354-9. doi: 10.1177/1533317506292372. Am J Alzheimers Dis Other Demen. 2006. PMID: 17062555 Free PMC article. Review.
-
The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.CNS Drugs. 2005;19(12):989-96. doi: 10.2165/00023210-200519120-00002. CNS Drugs. 2005. PMID: 16332141 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
